Protease-Activated Receptors – Key Regulators of Inflammatory Bowel Diseases Progression

References

• Lu JT, Xu AT, Shen J, Ran ZH. Crosstalk between intestinal epithelial cell and adaptive immune cell in intestinal mucosal immunity. J Gastroenterol Hepatol. 2017;32(5):975–980. doi:10.1111/jgh.13723
   PubMed Web of Science ®Google Scholar
• Xie Y, Chen L, Lv X, et al. The levels of serine proteases in colon tissue interstitial fluid and serum serve as an indicator of colorectal cancer progression. Oncotarget. 2016;7(22):32592–32606. doi:10.18632/oncotarget.8693
   PubMed Web of Science ®Google Scholar
• Curciarello R, Sobande T, Jones S, et al. Human neutrophil elastase proteolytic activity in ulcerative colitis favors the loss of function of therapeutic monoclonal antibodies. J Inflamm Res. 2020;13:233–243. doi:10.2147/jir.s234710
   PubMed Web of Science ®Google Scholar
• Pedersen G, Saermark T, Kirkegaard T, Brynskov J. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol. 2009;155(2):257–265. doi:10.1111/j.1365-2249.2008.03836.x
   PubMed Web of Science ®Google Scholar
• Meijer MJ, Mieremet-Ooms MA, van der Zon AM, et al. Increased mucosal matrix metalloproteinase-1, −2, −3 and −9 activity in patients with inflammatory bowel disease and the relation with Crohn’s disease phenotype. Dig Liver Dis. 2007;39(8):733–739. doi:10.1016/j.dld.2007.05.010
   PubMedGoogle Scholar
• Rath T, Roderfeld M, Graf J, et al. Enhanced expression of MMP-7 and MMP-13 in inflammatory bowel disease: a precancerous potential? Inflamm Bowel Dis. 2006;12(11):1025–1035. doi:10.1097/01.mib.0000234133.97594.04
   PubMed Web of Science ®Google Scholar
• Yablecovitch D, Kopylov U, Lahat A, et al. Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn’s disease, a post hoc analysis. Therap Adv Gastroenterol. 2019;12:1756284819881590. doi:10.1177/1756284819881590
   Web of Science ®Google Scholar
• Biancheri P, Brezski RJ, Di Sabatino A, et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology. 2015;149(6):1564–1574.e3. doi:10.1053/j.gastro.2015.07.002
   PubMed Web of Science ®Google Scholar
• Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs. 2005;65(16):2253–2286. doi:10.2165/00003495-200565160-00002
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11(4):243–255. doi:10.1038/nrgastro.2013.253
   PubMed Web of Science ®Google Scholar
• Guerra I, Bermejo F. Management of inflammatory bowel disease in poor responders to infliximab. Clin Exp Gastroenterol. 2014;7:359–367. doi:10.2147/ceg.s45297
   PubMedGoogle Scholar
• Jablaoui A, Kriaa A, Mkaouar H, et al. Fecal serine protease profiling in inflammatory bowel diseases. Front Cell Infect Microbiol. 2020;10:21. doi:10.3389/fcimb.2020.00021
   PubMed Web of Science ®Google Scholar
• Motta JP, Rolland C, Edir A, et al. Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation. Mucosal Immunol. 2021;14(3):667–678. doi:10.1038/s41385-021-00375-w
   PubMed Web of Science ®Google Scholar
• Motta JP, Palese S, Giorgio C, et al. Increased mucosal thrombin is associated with crohn’s disease and causes inflammatory damage through protease-activated receptors activation. J Crohns Colitis. 2021;15(5):787–799. doi:10.1093/ecco-jcc/jjaa229
   PubMed Web of Science ®Google Scholar
• Denadai-Souza A, Bonnart C, Tapias NS, et al. Functional proteomic profiling of secreted serine proteases in health and inflammatory bowel disease. Sci Rep. 2018;8(1):7834. doi:10.1038/s41598-018-26282-y
   PubMedGoogle Scholar
• Galipeau HJ, Caminero A, Verdu EF. Increased bacterial proteolytic activity detected before diagnosis of ulcerative colitis. Inflamm Bowel Dis. 2021;12:e144. doi:10.1093/ibd/izab144
   Google Scholar
• Galipeau HJ, Caminero A, Turpin W, et al. Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis. Gastroenterology. 2021;160(5):1532–1545. doi:10.1053/j.gastro.2020.12.004
   PubMed Web of Science ®Google Scholar
• Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64(6):1057–1068. doi:10.1016/0092-8674(91)90261-v
   PubMed Web of Science ®Google Scholar
• Gerszten RE, Chen J, Ishii M, et al. Specificity of the thrombin receptor for agonist peptide is defined by its extracellular surface. Nature. 1994;368(6472):648–651. doi:10.1038/368648a0
   PubMed Web of Science ®Google Scholar
• Blackhart BD, Emilsson K, Nguyen D, et al. Ligand cross-reactivity within the protease-activated receptor family. J Biol Chem. 1996;271(28):16466–16471. doi:10.1074/jbc.271.28.16466
   PubMed Web of Science ®Google Scholar
• O’Brien PJ, Prevost N, Molino M, et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem. 2000;275(18):13502–13509. doi:10.1074/jbc.275.18.13502
   PubMed Web of Science ®Google Scholar
• Paing MM, Stutts AB, Kohout TA, Lefkowitz RJ, Trejo J. Beta -Arrestins regulate protease-activated receptor-1 desensitization but not internalization or Down-regulation. J Biol Chem. 2002;277(2):1292–1300. doi:10.1074/jbc.M109160200
   PubMed Web of Science ®Google Scholar
• Wang P, DeFea KA. Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry. 2006;45(31):9374–9385. doi:10.1021/bi0602617
   PubMed Web of Science ®Google Scholar
• Kaneider NC, Leger AJ, Agarwal A, et al. ‘Role reversal’ for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol. 2007;8(12):1303–1312. doi:10.1038/ni1525
   PubMed Web of Science ®Google Scholar
• Jensen DD, Zhao P, Jimenez-Vargas NN, et al. Protein Kinase D and Gβγ Subunits Mediate Agonist-evoked Translocation of Protease-activated Receptor-2 from the Golgi Apparatus to the Plasma Membrane. J Biol Chem. 2016;291(21):11285–11299. doi:10.1074/jbc.M115.710681
   PubMed Web of Science ®Google Scholar
• Mulè F, Pizzuti R, Capparelli A, Vergnolle N. Evidence for the presence of functional protease activated receptor 4 (PAR4) in the rat colon. Gut. 2004;53(2):229–234. doi:10.1136/gut.2003.021899
   PubMed Web of Science ®Google Scholar
• Chin AC, Lee WY, Nusrat A, Vergnolle N, Parkos CA. Neutrophil-mediated activation of epithelial protease-activated receptors-1 and −2 regulates barrier function and transepithelial migration. J Immunol. 2008;181(8):5702–5710. doi:10.4049/jimmunol.181.8.5702
   PubMed Web of Science ®Google Scholar
• Dabek M, Ferrier L, Roka R, et al. Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. Am J Pathol. 2009;175(1):207–214. doi:10.2353/ajpath.2009.080986
   PubMed Web of Science ®Google Scholar
• Saeed MA, Ng GZ, Däbritz J, et al. Protease-activated Receptor 1 Plays a Proinflammatory Role in Colitis by Promoting Th17-related Immunity. Inflamm Bowel Dis. 2017;23(4):593–602. doi:10.1097/mib.0000000000001045
   PubMed Web of Science ®Google Scholar
• Cenac N, Coelho AM, Nguyen C, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol. 2002;161(5):1903–1915. doi:10.1016/s0002-9440(10)64466-5
   PubMed Web of Science ®Google Scholar
• Maeda S, Ohno K, Uchida K, et al. Intestinal protease-activated receptor-2 and fecal serine protease activity are increased in canine inflammatory bowel disease and may contribute to intestinal cytokine expression. J Vet Med Sci. 2014;76(8):1119–1127. doi:10.1292/jvms.14-0060
   PubMed Web of Science ®Google Scholar
• Kim JA, Choi SC, Yun KJ, et al. Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm Bowel Dis. 2003;9(4):224–229. doi:10.1097/00054725-200307000-00002
   PubMed Web of Science ®Google Scholar
• Ke Z, Wang C, Wu T, Wang W, Yang Y, Dai Y. PAR2 deficiency enhances myeloid cell-mediated immunosuppression and promotes colitis-associated tumorigenesis. Cancer Lett. 2020;469:437–446. doi:10.1016/j.canlet.2019.11.015
   PubMed Web of Science ®Google Scholar
• Tahara T, Shibata T, Nakamura M, et al. Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). Clin Exp Med. 2009;9(2):125–130. doi:10.1007/s10238-008-0025-x
   PubMed Web of Science ®Google Scholar
• Gould NJ, Davidson KL, Nwokolo CU, Arasaradnam RP. A systematic review of the role of DNA methylation on inflammatory genes in ulcerative colitis. Epigenomics. 2016;8(5):667–684. doi:10.2217/epi-2016-0006
   PubMed Web of Science ®Google Scholar
• Fiorucci S, Mencarelli A, Palazzetti B, et al. Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci U S A. 2001;98(24):13936–13941. doi:10.1073/pnas.241377298
   PubMed Web of Science ®Google Scholar
• Cenac N, Cellars L, Steinhoff M, et al. Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis. 2005;11(9):792–798. doi:10.1097/01.mib.0000177506.71784.bd
   PubMed Web of Science ®Google Scholar
• Christerson U, Keita AV, Söderholm JD, Gustafson-Svärd C. Increased expression of protease-activated receptor-2 in mucosal mast cells in Crohn’s ileitis. J Crohns Colitis. 2009;3(2):100–108. doi:10.1016/j.crohns.2008.11.003
   PubMed Web of Science ®Google Scholar
• Patel M, Shah G. Investigation of Possible Role of the PAR-2 Receptor in Intestinal Inflammation. J Young Pharm. 2010;2(1):54–58. doi:10.4103/0975-1483.62214
   PubMedGoogle Scholar
• Feng BS, Wu YJ, Zeng XH, et al. Bcl2L12 mediates effects of protease-activated receptor-2 on the pathogenesis of Th2-dominated responses of patients with ulcerative colitis. Arch Biochem Biophys. 2018;657:8–14. doi:10.1016/j.abb.2018.09.003
   PubMed Web of Science ®Google Scholar
• Liu B, Yang MQ, Yu TY, et al. Mast Cell Tryptase Promotes Inflammatory Bowel Disease-Induced Intestinal Fibrosis. Inflamm Bowel Dis. 2021;27(2):242–255. doi:10.1093/ibd/izaa125
   PubMed Web of Science ®Google Scholar
• Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116(5):1310–1316. doi:10.1172/jci21404
   PubMed Web of Science ®Google Scholar
• Mari B, Guerin S, Far DF, et al. Thrombin and trypsin-induced Ca(2+) mobilization in human T cell lines through interaction with different protease-activated receptors. FASEB j. 1996;10(2):309–316. doi:10.1096/fasebj.10.2.8641564
   PubMed Web of Science ®Google Scholar
• Christerson U, Keita AV, Söderholm JD, Gustafson-Svärd C. Potential role of protease-activated receptor-2-stimulated activation of cytosolic phospholipase A(2) in intestinal myofibroblast proliferation: implications for stricture formation in Crohn’s disease. J Crohns Colitis. 2009;3(1):15–24. doi:10.1016/j.crohns.2008.10.002
   PubMed Web of Science ®Google Scholar
• Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR. Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol. 2005;166(2):409–419. doi:10.1016/s0002-9440(10)62264-x
   PubMed Web of Science ®Google Scholar
• Graham WV, Wang F, Clayburgh DR, et al. Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events. Characterization of the human long myosin light chain kinase promoter. J Biol Chem. 2006;281(36):26205–26215. doi:10.1074/jbc.M602164200
   PubMed Web of Science ®Google Scholar
• Blair SA, Kane SV, Clayburgh DR, Turner JR. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest. 2006;86(2):191–201. doi:10.1038/labinvest.3700373
   PubMed Web of Science ®Google Scholar
• Gecse K, Róka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. 2008;57(5):591–599. doi:10.1136/gut.2007.140210
   PubMed Web of Science ®Google Scholar
• Róka R, Rosztóczy A, Leveque M, et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2007;5(5):550–555. doi:10.1016/j.cgh.2006.12.004
   PubMed Web of Science ®Google Scholar
• Dabek M, Ferrier L, Annahazi A, et al. Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: role of cathepsin G and protease-activated receptor-4. Inflamm Bowel Dis. 2011;17(6):1409–1414. doi:10.1002/ibd.21454
   PubMed Web of Science ®Google Scholar
• Sébert M, Denadai-Souza A, Quaranta M, et al. Thrombin modifies growth, proliferation and apoptosis of human colon organoids: a protease-activated receptor 1- and protease-activated receptor 4-dependent mechanism. Br J Pharmacol. 2018;175(18):3656–3668. doi:10.1111/bph.14430
   PubMed Web of Science ®Google Scholar
• Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn’s disease by tumour necrosis factor alpha antibody treatment. Gut. 2004;53(9):1295–1302. doi:10.1136/gut.2003.036632
   PubMed Web of Science ®Google Scholar
• Dirisina R, Katzman RB, Goretsky T, et al. p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis. Gastroenterology. 2011;141(3):1036–1045. doi:10.1053/j.gastro.2011.05.032
   PubMed Web of Science ®Google Scholar
• Kim JJ, Lee SB, Park JK, Yoo YD. TNF-alpha-induced ROS production triggering apoptosis is directly linked to Romo1 and Bcl-X(L). Cell Death Differ. 2010;17(9):1420–1434. doi:10.1038/cdd.2010.19
   PubMed Web of Science ®Google Scholar
• Iablokov V, Hirota CL, Peplowski MA, et al. Proteinase-activated receptor 2 (PAR2) decreases apoptosis in colonic epithelial cells. J Biol Chem. 2014;289(49):34366–34377. doi:10.1074/jbc.M114.610485
   PubMed Web of Science ®Google Scholar
• Her JY, Lee Y, Kim SJ, et al. Blockage of protease-activated receptor 2 exacerbates inflammation in high-fat environment partly through autophagy inhibition. Am J Physiol Gastrointest Liver Physiol. 2021;320(1):G30–g42. doi:10.1152/ajpgi.00203.2020
   PubMed Web of Science ®Google Scholar
• Schmid W, Vogelsang H, Papay P, et al. Increased responsiveness to thrombin through protease-activated receptors (PAR)-1 and −4 in active Crohn’s disease. J Crohns Colitis. 2014;8(6):495–503. doi:10.1016/j.crohns.2013.11.001
   PubMed Web of Science ®Google Scholar
• Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375(9715):657–663. doi:10.1016/s0140-6736(09)61963-2
   PubMed Web of Science ®Google Scholar
• Conlan MG, Haire WD, Burnett DA. Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci. 1989;34(7):1089–1093. doi:10.1007/bf01536380
   PubMed Web of Science ®Google Scholar
• Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn’s disease. Blood Coagul Fibrinolysis. 1992;3(6):773–778. doi:10.1097/00001721-199212000-00011
   PubMed Web of Science ®Google Scholar
• Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology. 1994;106(4):840–845. doi:10.1016/0016-5085(94)90741-2
   PubMed Web of Science ®Google Scholar
• Danese S, Katz JA, Saibeni S, et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut. 2003;52(10):1435–1441. doi:10.1136/gut.52.10.1435
   PubMed Web of Science ®Google Scholar
• Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem. 2000;275(10):6819–6823. doi:10.1074/jbc.275.10.6819
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–535. doi:10.1136/gut.48.4.526
   PubMed Web of Science ®Google Scholar
• Fala L. Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death. Am Health Drug Benefits. 2015;8(SpecFeature):148–151.
   PubMedGoogle Scholar
• O’Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial. Circulation. 2011;123(17):1843–1853. doi:10.1161/circulationaha.110.000786
   PubMed Web of Science ®Google Scholar
• Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J. 2010;31(21):2601–2613. doi:10.1093/eurheartj/ehq320
   PubMed Web of Science ®Google Scholar